FDA-cleared profile

iCAC Device

Bunkerhill, Inc · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Adjunctive opportunistic coronary-calcium estimation during routine chest CT review, providing informational segmentation and Agatston estimates for physician assessment rather than a stand-alone diagnosis.

Clinical role
Adjunctive informational support for radiologist review in the standard workflow; the original patient report and CT remain available and physician review is required.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: The cleared input is routine non-gated, non-contrast chest CT in patients aged 30 years and above. Results are informational and not intended for stand-alone clinical decision-making; the reviewed FDA validation used paired non-gated chest CT and gated coronary CT studies and should not be generalized beyond the described population and workflow.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adjunctive opportunistic coronary-calcium estimation during routine chest CT review, providing informational segmentation and Agatston estimates for physician assessment rather than a stand-alone diagnosis.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Adult non-gated, non-contrast chest CT scans in DICOM format, transferred from an imaging database such as PACS or a DICOM router; the labeled age is 30 years and above.
  • Who uses it?Intended users: Qualified medical professionals, including radiologists and interpreting physicians.
  • What does the software produce?Output: An informational visual representation of estimated coronary-artery-calcium segmentation plus exact and four-category quantitative estimates of coronary calcium burden in Agatston units, viewable in the patient report and diagnostic image viewer.
  • What is its most important limitation?Key limitation: The cleared input is routine non-gated, non-contrast chest CT in patients aged 30 years and above. Results are informational and not intended for stand-alone clinical decision-making; the reviewed FDA validation used paired non-gated chest CT and gated coronary CT studies and should not be generalized beyond the described population and workflow.

Clinical takeaway. Clinical role: Adjunctive opportunistic coronary-calcium estimation during routine chest CT review, providing informational segmentation and Agatston estimates for physician assessment rather than a stand-alone diagnosis.

Evidence takeaway. Evidence from the reviewed source record: FDA validation used 762 paired studies from nine geographically diverse sites. Overall category alignment was 79.7%, and category-level positive predictive value ranged from 68.1% to 90.1%; the submission acceptance criteria were at least 73% alignment and at least 65% PPV for each category.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adjunctive opportunistic coronary-calcium estimation during routine chest CT review, providing informational segmentation and Agatston estimates for physician assessment rather than a stand-alone diagnosis.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Adjunctive informational support for radiologist review in the standard workflow; the original patient report and CT remain available and physician review is required.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Adult non-gated, non-contrast chest CT scans in DICOM format, transferred from an imaging database such as PACS or a DICOM router; the labeled age is 30 years and above.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
An informational visual representation of estimated coronary-artery-calcium segmentation plus exact and four-category quantitative estimates of coronary calcium burden in Agatston units, viewable in the patient report and diagnostic image viewer.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Medical facilities providing routine-care non-gated, non-contrast chest CT and physician interpretation.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Qualified medical professionals, including radiologists and interpreting physicians.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The cleared input is routine non-gated, non-contrast chest CT in patients aged 30 years and above. Results are informational and not intended for stand-alone clinical decision-making; the reviewed FDA validation used paired non-gated chest CT and gated coronary CT studies and should not be generalized beyond the described population and workflow.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
FDA validation used 762 paired studies from nine geographically diverse sites. Overall category alignment was 79.7%, and category-level positive predictive value ranged from 68.1% to 90.1%; the submission acceptance criteria were at least 73% alignment and at least 65% PPV for each category.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA validation used 762 paired studies from nine geographically diverse sites. Overall category alignment was 79.7%, and category-level positive predictive value ranged from 68.1% to 90.1%; the submission acceptance criteria were at least 73% alignment and at least 65% PPV for each category.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The FDA summary reports alignment and PPV for calcium categories rather than a disease-detection sensitivity measure.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The FDA summary reports alignment and PPV for calcium categories rather than a disease-detection specificity measure.

Overall category alignment

0.797 proportion

  • EndpointOverall alignment between estimated coronary calcium category and paired reference
  • Population762 paired non-gated non-contrast chest CT and gated coronary CT studies from nine geographically diverse sites
  • Tested versioniCAC Device configuration submitted in K230223

Category PPV lower endpoint

0.681 proportion

  • EndpointLowest reported positive predictive value among the four calcium categories
  • Population762 paired non-gated non-contrast chest CT and gated coronary CT studies from nine geographically diverse sites
  • Tested versioniCAC Device configuration submitted in K230223

Category PPV upper endpoint

0.901 proportion

  • EndpointHighest reported positive predictive value among the four calcium categories
  • Population762 paired non-gated non-contrast chest CT and gated coronary CT studies from nine geographically diverse sites
  • Tested versioniCAC Device configuration submitted in K230223

iCAC Device paired-study validation

  • DesignRetrospective paired-study validation comparing routine non-gated, non-contrast chest CT estimates with paired gated coronary CT reference categories and Agatston measurements.
  • Population762 paired CT studies from nine geographically diverse sites, with the calcium categories represented in the validation set.
  • Scopeexact submission
  • Tested versioniCAC Device configuration submitted in K230223
  • Samplen=762
  • Sites9
  • IndependenceSponsor or vendor study

K230223

The lower and upper PPV values are endpoints of the reported category span, not a single across-case range metric or a full-paper clinical-outcomes study.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

Reimbursement
Service-level context: CMS Transmittal 13702 (March 2026) establishes HCPCS G0680 under the hospital outpatient payment system, effective 2026-04-01, for software analysis of coronary artery calcium and/or aortic valve calcification from chest CT. Bunkerhill Health's 2026-04-15 release says CMS created a national billing code and payment for this analysis. CMS names no product, and the release does not name iCAC or state a code number. This is context for the service, not a determination that this product or release is covered or paid. No payment amount, status indicator or APC was read.
  • Service-level, not product-specific
  • Checked 2026-10-26
IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult non-gated, non-contrast chest CT scans in DICOM format, transferred from an imaging database such as PACS or a DICOM router; the labeled age is 30 years and above.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K230223: iCAC Device

  2. Routing

    Source context, not route validation: The standalone SaMD receives DICOM from PACS or a DICOM router and can present the estimated score or category in a patient report, the segmentation in a diagnostic viewer, and an optional DICOM Secondary Capture series.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K230223: iCAC Device

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The FDA summary establishes a standalone SaMD and DICOM/PACS-router workflow but does not establish the current exact configuration's hosting model.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 ·

  4. Returned objects

    Source context, not route validation: An informational visual representation of estimated coronary-artery-calcium segmentation plus exact and four-category quantitative estimates of coronary calcium burden in Agatston units, viewable in the patient report and diagnostic image viewer.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K230223: iCAC Device

  5. Viewer/worklist/report

    Unresolved route: An informational visual representation of estimated coronary-artery-calcium segmentation plus exact and four-category quantitative estimates of coronary calcium burden in Agatston units, viewable in the patient report and diagnostic image viewer.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K230223: iCAC Device

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The standalone SaMD receives DICOM from PACS or a DICOM router and can present the estimated score or category in a patient report, the segmentation in a diagnostic viewer, and an optional DICOM Secondary Capture series.
  • Exact FDA submission
  • Checked 2026-09-07
Security
Bunkerhill Health's website states SOC 2 Type II certification, HIPAA compliance and ISO/IEC 27001:2022 certification. Badges only: no scope, dates or controls are given. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

PACS or DICOM-router input

The cleared standalone SaMD receives routine non-gated, non-contrast chest CT through DICOM transfer from an imaging database such as PACS or a DICOM router and can return report, viewer and optional DICOM Secondary Capture outputs.

exact submission · checked 2026-09-07

Carebricks CAC workflow context

Bunkerhill states that its current Carebricks product uses the FDA-cleared iCAC algorithm to detect and quantify CAC on routine non-gated chest CT and describes follow-up prioritization and care coordination for health systems.

product family · checked 2026-09-07

This vendor announcement supports current family workflow context; it does not establish exact K230223 release performance, installation, price, security or support terms.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K230223
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-04-25
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-07Last searched
24Fields reviewed
12Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

Stored candidate metadata was screened. The broad iCAC query returned 20 PubMed and 10 trial identifiers without exact K230223 linkage established in metadata; no full paper or trial record was reviewed, and no candidate is promoted as product evidence. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor announcement, stored candidate metadata, literature index, trial registry, payer policy, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public price or quote for the exact K230223 configuration was reviewed.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not publicly available - checked 2026-09-07 - Exact FDA submission

    The FDA summary establishes a standalone SaMD and DICOM/PACS-router workflow but does not establish the current exact configuration's hosting model.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

10 sources - 3 history items

Source ledger

  1. FDA 510(k) K230223: iCAC Device

    U.S. Food and Drug Administration - Published 2023-04-25 - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. iCAC Device model card (K230223)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Bunkerhill and Cleerly strategic partnership for iCAC

    Bunkerhill Health - Published 2025-03-04 - Accessed 2026-09-08

    Scope: productFamily, implementationCapabilities

  8. Bunkerhill Health home page security claims

    Bunkerhill Health - Accessed 2026-10-25

    Scope: security

  9. CMS Transmittal 13702 (CR 14380): April 2026 Update of the Hospital Outpatient Prospective Payment System

    Centers for Medicare & Medicaid Services - Published 2026-03-27 - Accessed 2026-10-26

    Scope: reimbursement, payerPolicy

  10. Bunkerhill news release: CMS reimbursement pathway for AI cardiovascular analysis

    Bunkerhill Health - Published 2026-04-15 - Accessed 2026-10-26

    Scope: reimbursement

Research history

  1. K230223 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28
FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27
FDA-cleared K251656

Careverse CoronaryDoc (Careverse CoronaryDoc)

Careverse Technology Pte. Ltd.

Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-09-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history